2021
RBC alloimmunization and daratumumab: Are efforts to eliminate interferences and prevent new antibodies necessary?
Lee ES, Hendrickson JE, Tormey CA. RBC alloimmunization and daratumumab: Are efforts to eliminate interferences and prevent new antibodies necessary? Transfusion 2021, 61: 3283-3285. PMID: 34767268, DOI: 10.1111/trf.16736.Peer-Reviewed Original ResearchConceptsRBC alloimmunization
2019
The Presence and Persistence of Pregnancy-Associated Red Blood Cell Alloantibodies in Blood Donors
Balbuena-Merle R, Hauser R, Karafin M, Tan S, Spencer B, Roubinian N, Wu Y, Triulzi D, Kleinman S, Gottschall J, Tormey C, Hendrickson J. The Presence and Persistence of Pregnancy-Associated Red Blood Cell Alloantibodies in Blood Donors. Blood 2019, 134: 2452. DOI: 10.1182/blood-2019-121388.Peer-Reviewed Original ResearchRBC alloantibodiesTransfusion historyBlood donorsBlood donor databasePregnant femalesPersistent antibodiesPrior transfusionsPrior pregnancyAntibody screenMean durationPregnancy historyFemale healthy blood donorsRed blood cell alloantibodiesDonor databaseMean timeAntibody screen resultsHealthy blood donorsUS blood centersSubsequent donationsMajority of donorsSubsequent blood donationsAlloantibody specificitiesRBC alloimmunizationCell microchimerismAntigen exposureTransfusion-related red blood cell alloantibodies: induction and consequences
Tormey CA, Hendrickson JE. Transfusion-related red blood cell alloantibodies: induction and consequences. Blood 2019, 133: 1821-1830. PMID: 30808636, PMCID: PMC6484385, DOI: 10.1182/blood-2018-08-833962.Peer-Reviewed Original ResearchConceptsTransfusion recipientsBlood donorsPreventative strategiesBlood product exposureCompatible RBC unitsRBC alloantibody formationHemolytic transfusion reactionsDevelopment of alloantibodiesAdaptive immune factorsJudicious transfusionRBC alloimmunizationImmunomodulatory therapyAlloantibody formationBlood transfusionRBC alloantibodiesRecipient variablesFuture pregnanciesImmune factorsTransfusion reactionsBlood productsHemolytic diseaseFuture transfusionsHuman studiesTransfusionAlloantibodies
2017
B cells require Type 1 interferon to produce alloantibodies to transfused KEL‐expressing red blood cells in mice
Gibb DR, Liu J, Santhanakrishnan M, Natarajan P, Madrid DJ, Patel S, Eisenbarth SC, Tormey CA, Stowell SR, Iwasaki A, Hendrickson JE. B cells require Type 1 interferon to produce alloantibodies to transfused KEL‐expressing red blood cells in mice. Transfusion 2017, 57: 2595-2608. PMID: 28836263, PMCID: PMC5745367, DOI: 10.1111/trf.14288.Peer-Reviewed Original ResearchConceptsBone marrow chimeric miceHuman KEL glycoproteinType 1 interferonB cellsMean fluorescence intensityChimeric miceRed blood cell antigensBlood cell antigensGerminal center B cellsWT B cellsRBC alloimmunizationIgG alloantibodiesAlloimmune responseB cell differentiationRed blood cellsTransfusion protocolControl miceInflammatory stateWT miceAutoimmune pathologyIgG productionIFNAR1 expressionPlasma cellsAntiviral immunityInflammatory stimuliThe impact of vaccination on RBC alloimmunization in a murine model
Natarajan P, Santhanakrishnan M, Tormey CA, Hendrickson JE. The impact of vaccination on RBC alloimmunization in a murine model. Vox Sanguinis 2017, 112: 598-600. PMID: 28597520, PMCID: PMC5575953, DOI: 10.1111/vox.12541.Peer-Reviewed Original ResearchConceptsImmune responseMurine modelRBC alloantibody formationDamage-associated molecular patternsImpact of vaccinationRBC alloimmunizationAlloantibody formationHepB vaccineRBC transfusionAdaptive immunityAnimal modelsAlloimmunizationMolecular patternsVaccineVaccinationFuture studiesResponseTransfusionImmunity
2016
Understanding red blood cell alloimmunization triggers
Hendrickson JE, Tormey CA. Understanding red blood cell alloimmunization triggers. Hematology 2016, 2016: 446-451. PMID: 27913514, PMCID: PMC6142457, DOI: 10.1182/asheducation-2016.1.446.Peer-Reviewed Original ResearchConceptsRBC alloimmunizationRed blood cellsRisk factorsBlood cellsWhite blood cellsBlood group antigensPregnancy outcomesAlloantibody formationRBC alloantibodiesRBC transfusionRecipient factorsTransfusion safetyAlloimmunizationAnimal modelsHuman studiesPrevention strategiesDonor plasmaDanger signalsParticular antigenGroup antigensAntigenTransfusionPregnancyNonrespondersCellsThe Nlrp3 Inflammasome Does Not Regulate Alloimmunization to Transfused Red Blood Cells in Mice
Gibb DR, Calabro S, Liu D, Tormey CA, Spitalnik SL, Zimring JC, Hendrickson JE, Hod EA, Eisenbarth SC. The Nlrp3 Inflammasome Does Not Regulate Alloimmunization to Transfused Red Blood Cells in Mice. EBioMedicine 2016, 9: 77-86. PMID: 27345021, PMCID: PMC4972549, DOI: 10.1016/j.ebiom.2016.06.008.Peer-Reviewed Original ResearchConceptsRBC transfusionNLRP3 inflammasomeRed blood cell transfusionInnate immune cell activationPro-inflammatory pathogensMolecular patternsBlood cell transfusionProduction of alloantibodiesTransfusion-associated mortalityImmune cell activationInnate immune stimuliBlood group antigensBone marrow failureAlloantibody productionRBC alloimmunizationAlloantibody responsesCell transfusionAlloimmune responseRed blood cellsABO matchingImmunological factorsInflammatory conditionsLeading causeImmune stimuliEndogenous DAMPRed Blood Cell Antibodies in Hematology/Oncology Patients Interpretation of Immunohematologic Tests and Clinical Significance of Detected Antibodies
Hendrickson JE, Tormey CA. Red Blood Cell Antibodies in Hematology/Oncology Patients Interpretation of Immunohematologic Tests and Clinical Significance of Detected Antibodies. Hematology/Oncology Clinics Of North America 2016, 30: 635-651. PMID: 27113001, DOI: 10.1016/j.hoc.2016.01.006.Peer-Reviewed Original ResearchConceptsRed blood cell transfusionRed blood cell antibodiesRBC alloimmunization rateBlood cell transfusionManagement of patientsDevelopment of alloantibodiesBlood group antigensAlloimmunization rateRBC alloimmunizationSuch alloantibodiesCell transfusionCell antibodiesClinical significanceHemolytic anemiaPatients' interpretationsDetected antibodiesTransfusionGroup antigensBlood bankCompatible unitsAntibodiesAlloantibodiesOncology disordersDeleterious consequencesAlloimmunization
2015
Riboflavin‐ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells
Tormey CA, Santhanakrishnan M, Smith NH, Liu J, Marschner S, Goodrich RP, Hendrickson JE. Riboflavin‐ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells. Transfusion 2015, 56: 863-872. PMID: 26643781, DOI: 10.1111/trf.13432.Peer-Reviewed Original ResearchConceptsWhite blood cellsFresh whole bloodPathogen reduction treatmentAlloimmune responseWhole bloodRBC antigensSyngeneic RBCsNegative direct antiglobulin testBlood cellsRBC antigen expressionRecipient alloimmune responsesDirect antiglobulin testMurine red blood cellsPathogen inactivation treatmentPosttransfusion RBC recoveryKEL RBCsRBC alloimmunizationImmunogenic neoantigensRed blood cellsAntiglobulin testBlood donorsImmune responseAntigen expressionHours posttransfusionHuman antigensA Novel Network Analysis Tool to Identify Relationships Between Disease States and Risk for RBC Alloimmunization
Celli R, Schulz W, Hendrickson J, Tormey C. A Novel Network Analysis Tool to Identify Relationships Between Disease States and Risk for RBC Alloimmunization. Blood 2015, 126: 2349. DOI: 10.1182/blood.v126.23.2349.2349.Peer-Reviewed Original ResearchDisease statesControl cohortAcute myeloid leukemia/myelodysplastic syndromeLeukemia/myelodysplastic syndromeRed blood cell alloimmunizationChronic transfusion supportHyper-responder groupAcute renal failureAML/MDSAcute myocardial infarctionICD-9 codesDevelopment of alloantibodiesSpecific medical conditionsElectronic medical recordsSignificant disease associationCertain disease statesAlloimmunized individualsRBC alloimmunizationGastrointestinal bleedPulmonary hypertensionRenal failureTransfusion burdenTransfusion supportMale patientsRBC transfusion
2014
The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders
Gehrie EA, Tormey CA. The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders. Transfusion Medicine And Hemotherapy 2014, 41: 420-429. PMID: 25670929, PMCID: PMC4280450, DOI: 10.1159/000369109.Peer-Reviewed Original ResearchRed blood cellsPatient populationInfluence of ClinicalDevelopment of antibodiesImportant clinical consequencesDiverse patient populationsBlood group antigensRBC alloimmunizationChronic transfusionRBC alloantibodiesHyper respondersClinical circumstancesClinical consequencesAlloimmunizationMedical literatureTransfusionAlloantibodiesGroup antigensRespondersBlood cellsTransfusion medicinePatientsBiological factorsIndividualsPregnancyRed Blood Cell Alloimmunization Mitigation Strategies
Hendrickson JE, Tormey CA, Shaz BH. Red Blood Cell Alloimmunization Mitigation Strategies. Transfusion Medicine Reviews 2014, 28: 137-144. PMID: 24928468, DOI: 10.1016/j.tmrv.2014.04.008.Peer-Reviewed Original ResearchConceptsHemolytic transfusion reactionsRBC alloantibodiesRBC alloimmunizationTransfusion reactionsImmune systemRed blood cell alloantibodiesCompatible RBC unitsRBC alloimmunization rateTransfusion-associated morbidityRecipient's immune systemTransfusion-associated deathForms of anemiaAlloimmunization rateAntigen exposureSignificant morbidityTransfusion recipientsHemolytic diseaseAlloantibodiesHuman studiesAnimal studiesDanger signalsAnimal dataMorbidityAlloimmunizationRBC units